Beyond Counting on Our Fingers: The Current State and Future Management of Oligometastatic Lung Cancer
There is a high degree of variability in the management and even the understanding of the oligometastatic state in lung malignancies, or indeed in the context of any solid tumor.
Category
  • Oligometastatic
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Red Journal Oncology Scans - 2024
The field of cancer is a rapidly evolving field with new treatment approaches moving to clinic on a daily basis. Radiation Oncology is no different. It is extremely difficult for a practicing clinician to stay abreast of new developments in cancer care.
Category
  • Breast
  • Gastrointestinal
  • Gynecologic
  • Head and Neck
  • Hematologic
  • Professional Development
  • Sarcoma
  • SBRT
  • Thoracic
Format
  • Journal Activities
Credits
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Certificate of Attendance
Cost $299.00
Prevention and Management of Toxicity in Organs at Risk (OAR) in a Community Setting
This activity focuses entirely on issues related to the Organs at Risk (OAR) in the setting of thoracic radiation. Discussion centers on protecting the OARs and managing acute and late toxicities. Each speaker focuses on a different clinical situation.
Category
  • SBRT
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Relevant or Relegated? Radiotherapy for Stage III NSCLC in the Neoadjuvant Era
There are many ongoing advances in the multidisciplinary management of stage III NSCLC, in particular the advent of neoadjuvant immunotherapy in patients who are resectable.
Category
  • Immunotherapy
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Multidisciplinary Management of Lung Cancer in the Patient with Interstitial Lung Disease
Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at increased risk of developing lung cancer. Management of lung cancer in patients with ILD is particularly challenging.
Category
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Optimizing Sequencing in Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer – Clinical and Translational Advances
This combined immunotherapy track and lung cancer track brings together leading experts to discuss recent, cutting-edge trials and strategies in treating both locally advanced and metastatic non-small cell lung cancer (NSCLC). Dr.
Category
  • Immunotherapy
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Multidisciplinary Lung Cancer Tumor Board: A Case-Based Discussion Spanning Bread-and-Butter through the Gray Zone
The management of locally advanced lung cancer increasingly relies on multidisciplinary collaboration. Advances in neoadjuvant and perioperative chemoimmunotherapy have significantly improved outcomes for patients with resectable non-small cell lung cancer.
Category
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Bringing Rationalism to Empiricism: A Discussion on Empiric SBRT for Early-Stage Lung Cancer
Lung cancer screening is resulting in a higher incidence of early-stage lung cancer diagnoses. This commonly occurs among older patients with chronic lung disease who are at high risk for complications with attaining pathologic confirmation.
Category
  • SBRT
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Certificate of Attendance
Cost $149.00
The Role for Consolidative Local Therapy in Stage IV Non-Small Cell Lung Cancer for Oligometastases and Beyond: How are We Improving Outcomes for Patients?
Patients with Stage IV Lung cancer vary in their response to the numerous systemic therapies and are living longer. The role of aggressive local therapy or metastatic directed therapy (MDT) is critical for radiation oncologists and surgeons.
Category
  • Oligometastatic
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Appropriateness Criteria for Radiotherapy in the Setting of Presumed Early-stage Lung Cancer
This activity provides practitioners with the knowledge of the treatment of lung mass without tissue diagnosis.
Category
  • Thoracic
Format
  • Journal Activities
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00

Pages